CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
1 research outputs found
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Author
A List
A Raza
+26Â more
A Raza
A Raza
Azra Raza
BD Cheson
BD Cheson
David P Steensma
Deborah Mulford
DP Steensma
E Laborde
F Ali-Osman
F Quddus
Gail L Brown
Guillermo Garcia-Manero
K Mrozek
M Stofega
Mikkael A Sekeres
N Galili
Naomi Galili
NCI Common Terminology Criteria for Adverse Events. Common Terminology Criteria for Adverse Events (CTCAE)
P Bernasconi
P Fenaux
P Greenberg
Ralph Boccia
Roger M Lyons
Ruben A Mesa
Scott E Smith
Publication venue
'Springer Science and Business Media LLC'
Publication date
Field of study
Get PDF
Crossref
Get PDF
